Showing results (1-10 of 11) with videos related to
Sort By:
Pageof 2
Health Policy (Amsterdam, Netherlands)|October 26, 2005
Demand and supply of emergency help: an economic analysis of Red Cross servicesFranz Hackl, Gerald Josef PrucknerHealth Economics|September 24, 2004
Warm glow, free-riding and vehicle neutrality in a health-related contingent valuation studyFranz Hackl, Gerald J PrucknerJournal of Health Economics|July 18, 2015
Old boys' network in general practitioners' referral behavior?Franz Hackl, Michael Hummer, Gerald J PrucknerHealth Economics|July 22, 2014
The Effectiveness of Health ScreeningFranz Hackl, Martin Halla, Michael Hummer, et al.Hepatology (Baltimore, Md.)|September 27, 2003
Survival in patients undergoing transjugular intrahepatic portosystemic shunt: ePTFE-covered stentgrafts versus bare stentsBernhard Angermayr, Manfred Cejna, Franz Koenig, et al.Wiener Klinische Wochenschrift|May 27, 2010
Antiviral treatment of chronic hepatitis C in clinical routineAndreas Maieron, Sigrid Metz-Gercek, Franz Hackl, et al.Wiener Klinische Wochenschrift|October 9, 2004
Retreatment of patients with chronic hepatitis C not responding to interferon/ribavirin combination therapy with daily interferon plus ribavirin plus amantadineRudolf E Stauber, Harald Hofer, Franz Hackl, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 20, 2005
Diagnostic value of quantitative hepatic copper determination in patients with Wilson's DiseasePeter Ferenci, Petra Steindl-Munda, Wolfgang Vogel, et al.Liver International : Official Journal of the International Association for the Study of the Liver|August 5, 2003
Impact of high-dose interferon induction and ribavirin therapy in patients with chronic hepatitis C relapsing after or not responding to interferon monotherapyPetra Steindl-Munda, Peter Ferenci, Harald Brunner, et al.Journal of Hepatology|December 13, 2005
Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naïve patients with chronic hepatitis C genotype 1 infectionPeter Ferenci, Elisabeth Formann, Hermann Laferl, et al.Pageof 2